talkbio – Talk Bio

Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial

17 hours ago talkbio0Tagged Administration, Oral, Agonist, amycretin, Amylin Receptor Agonists, Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Glycosylated hemoglobin A, Novo Nordisk, Phase 2 clinical trial, subcutaneous administration, Weight Loss

Novo Nordisk; Amycretin; Type 2 diabetes; Weight loss; HbA1c reduction; GLP-1 agonist; Amylin receptor agonist; Phase 2 clinical trial; Subcutaneous administration; Oral administration

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

17 hours ago talkbio0Tagged Investments, layoffs, Novartis, pharmaceutical manufacturing, restructuring, Schweizerhalle, Stein facility, Switzerland

Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment

Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect

17 hours ago talkbio0Tagged AstraZeneca, Centers for Medicare & Medicaid Services, drug price, Farxiga, Inflation, Medicare, negotiation, petition, pharmaceutical lawsuits, price controls, SCOTUS, Supreme Court

Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls

FDA’s Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement

21 hours ago talkbio0Tagged CNPV, Commissioner 's National Priority Voucher, Drug Approval Process, internal disagreement, legality, Pazdur, Tidmarsh, Tumor board, United States Food and Drug Administration

FDA; Pazdur; Commissioner’s National Priority Voucher; CNPV; legality; internal disagreement; tumor board; Tidmarsh; drug approval process

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

1 day ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

1 day ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

2 days ago talkbio0Tagged agentic AI, AI-guided, AWS HealthLake, Clinical Decision Support, DNA Integration, healthcare workflow, Malignant neoplasm of breast, Microsoft Teams, multi-agent systems, Neoplasms, Precision Medicine

agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

2 days ago talkbio0Tagged AI-discovered drugs, ATR, ATR/mTOR Inhibitors, Brain Neoplasms, CNS-penetrant, dual pathway inhibition, Enki generative AI, preclinical data, PTEN-deficient tumors, Rakovina, Society for Neuro-Oncology

Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

2 days ago talkbio0Tagged Alzheimer 's disease, Clinical Failure, Clinical Trials, discontinued, Johnson & Johnson, posdinemab, tau-targeting antibody

Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued